Oxford Nanopore London Calling Takeaways: Product offering strengthened including for GridION Q-line and PromethION, with further peptide progress highlighted. New Exec appointments encouraging

Research evidence excerpt

Oxford Nanopore London Calling Takeaways: Product offering strengthened including for GridION Q-line and PromethION, with further peptide progress highlighted. New Exec appointments encouraging

C A Z E N O V E Europe Equity Research

22 May 2026

Oxford Nanopore

London Calling Takeaways: Product offering Overweight

strengthened including for GridION Q-line and ONT.L, ONT LN

PromethION, with further peptide progress highlighted. Price (21 May 26):127p

New Exec appointments encouraging

European Pharmaceuticals &

Yesterday, we attended ONT’s London Calling Analyst Event. The company was Biotechnology

represented by CEO Francis Van Parys, CFO Nick Keher, and Chief Scientific Officer Zain Ebrahim AC

Lakmal Jayasinghe. Overall, we were encouraged by ONT’s progress across their (44-20) 3493-1163

portfolio including the announced launch of a higher throughput PromethION zain.ebrahim@jpmorgan.com

(PromethION Plus), an improved GridION Q-line product with additional features, Richard Vosser

continued interest in Biopharma QC as well as an updated AI-developed higher (44-20) 7742-6652

richard.vosser@jpmorgan.com

accuracy basecaller, v6.0. We were also encouraged by the appointments of Davide

Sophia Graeff Buhl Nielsen

Manissero as ONT’s first Chief Medical Officer, and Andrew Watson as Chief

(44-20) 7742-3918

Information Officer, adding to the strength and depth of the Executive Committee. sophia.graeffbuhlnielsen@jpmorgan.com

J.P. Morgan Securities plc

Details

• ONT announced the appointment of two senior executives, strengthening Specialist Sales contact details:

the Executive Committee: ONT announced the appointment of the Marjan Daeipour - Specialist Sales -

company’s first Chief Medical Officer (CMO), Davide Manissero, effective on European Healthcare

(44 20) 7134-1329